NEUTROGENA U.S. SALES ADVANCE PUSHES STOCK AHEAD 13.4% TO 19 IN SECOND QUARTER; COSMETICS INDEX MOVES AHEAD 3.9% AS MOST FIRMS REGISTER GAINS
This article was originally published in The Rose Sheet
Executive Summary
Neutrogena's rebounding U.S. sales and its focus on higher- margin "problem solver" products rekindled investor interest in the firm's stock in the second quarter.